Search

Your search keyword '"Gaballa, Mahmoud R."' showing total 28 results
Start Over Author "Gaballa, Mahmoud R."
28 results on '"Gaballa, Mahmoud R."'

1. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Jr., Larry D., and Lin, Yi

Published
2024
Full Text
View/download PDF

2. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma over Three Decades

Author

Pasvolsky, Oren, primary, Marcoux, Curtis, additional, Dai, Jianliang, additional, Milton, Denái R., additional, Tanner, Mark R., additional, Syed, Naureen, additional, Bashir, Qaiser, additional, Srour, Samer, additional, Saini, Neeraj, additional, Lin, Paul, additional, Ramdial, Jeremy, additional, Nieto, Yago, additional, Tang, Guilin, additional, Aljawai, Yosra, additional, Lee, Hans C., additional, Gaballa, Mahmoud R, additional, Patel, Krina K., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2024
Full Text
View/download PDF

4. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

Author

Gaballa, Mahmoud R., Ma, Junsheng, Rauf, Mikael, Bassett, Roland, Pasvolsky, Oren, Tanner, Mark R., Bashir, Qaiser, Srour, Samer A., Saini, Neeraj, Ramdial, Jeremy, Nieto, Yago, Murphy, Regan, Rezvani, Katayoun, Tang, Guilin, Lin, Pei, Lee, Hans C., Patel, Krina K., Ullah, Muhammad R., Kaufman, Gregory P., Manasanch, Elisabet E., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Shpall, Elizabeth J., Champlin, Richard E., Orlowski, Robert Z., and Qazilbash, Muzaffar H.

Published
2022
Full Text
View/download PDF

5. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Author

Gaballa, Mahmoud R., Banerjee, Pinaki, Milton, Denái R., Jiang, Xianli, Ganesh, Christina, Khazal, Sajad, Nandivada, Vandana, Islam, Sanjida, Kaplan, Mecit, Daher, May, Basar, Rafet, Alousi, Amin, Mehta, Rohtesh, Alatrash, Gheath, Khouri, Issa, Oran, Betul, Marin, David, Popat, Uday, Olson, Amanda, Tewari, Priti, Jain, Nitin, Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop, Chen, Ken, Champlin, Richard, Shpall, Elizabeth, Rezvani, Katayoun, and Kebriaei, Partow

Published
2022
Full Text
View/download PDF

6. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience

Author

Pasvolsky, Oren, Gaballa, Mahmoud R., Milton, Denái R., Masood, Adeel, Sami, Sophiya S., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Lin, Pei, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2023
Full Text
View/download PDF

9. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Author

Frigault, Matthew, primary, Rosenblatt, Jacalyn, additional, Dhakal, Binod, additional, Raje, Noopur, additional, Cook, Daniella, additional, Gaballa, Mahmoud R., additional, Emmanuel-Alejandro, Estelle, additional, Nissen, Danielle, additional, Cornwell, Christine, additional, Banerjee, Kamalika, additional, Rotte, Anand, additional, Heery, Christopher R., additional, Avigan, David, additional, Jakubowiak, Andrzej, additional, and Bishop, Michael R., additional

Published
2022
Full Text
View/download PDF

11. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

Author

Singh, Harjeet, primary, Srour, Samer A., additional, Milton, Denái R., additional, McCarty, Jessica, additional, Dai, Cuiping, additional, Gaballa, Mahmoud R., additional, Ammari, Mariam, additional, Olivares, Simon, additional, Huls, Helen, additional, De Groot, Eleanor, additional, Marin, David, additional, Petropoulos, Demetrios, additional, Olson, Amanda L., additional, Anderlini, Paolo, additional, Im, Jin S., additional, Khouri, Issa, additional, Hosing, Chitra M., additional, Rezvani, Katayoun, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Cooper, Laurence J. N., additional, and Kebriaei, Partow, additional

Published
2022
Full Text
View/download PDF

15. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T‐cell therapy.

Author

Dhawale, Tejaswini M., Johnson, P. Connor, Gaballa, Mahmoud R., Nelson, Ashley M., Lavoie, Mitchell W., Boateng, Kofi Y., Greydanus, Claire, Frigault, Matthew J., and El‐Jawahri, Areej

Subjects
CHIMERIC antigen receptors, POST-traumatic stress disorder, QUALITY of life, T cells, PSYCHOLOGICAL distress, POST-traumatic stress, PSYCHOLOGICAL adaptation
Abstract

Background: Chimeric antigen receptor (CAR) T‐cell is potentially curative therapy for patients with hematologic malignancies but can cause life‐threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking. Methods: The authors conducted a cross‐sectional study of patients receiving CAR‐T. Before hospitalization for CAR‐T, patients completed assessments of quality of life (QOL) (Functional Assessment of Cancer Therapy‐General), anxiety and depression symptoms (Hospital Anxiety and Depression Scale) and post‐traumatic stress disorder symptoms (Post‐Traumatic Stress Checklist). Patients also completed the Prognostic Awareness Impact Scale (PAIS), which measures three domains: cognitive understanding of prognosis, emotional coping with prognosis, and adaptive response. Results: A total of 71.8% (102 of 142) of eligible patients were enrolled. A total of 34% of patients reported that their oncologist said their cancer is curable and 64% reported there was >50% chance of cure. Overall, 26%, 30%, and 21% of patients reported clinically significant depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms, respectively. We found no association between patients' cognitive understanding of prognosis and QOL or mood. Higher emotional coping with prognosis was associated with better QOL (Β = 0.72; SE = 0.10; p = <.001) and lower depression (Β = −0.17; SE = 0.02; p = <.001), anxiety (Β = −0.21; SE = 0.02; p = <.001), and PTSD (Β = −0.43; SE = 0.06; p = <.001) symptoms. Higher adaptive response was associated with better QOL (Β = 0.19; SE = 0.09; p =.028) and lower depression (Β = −0.05; SE = 0.02; p =.023), anxiety (Β = −0.09; SE = 0.02; p = <.001), and PTSD (Β = −0.19; SE = 0.05; p = <.001) symptoms. Conclusions: Patients undergoing CAR‐T report overly optimistic perception of their prognosis and have high rates of psychological distress. Higher emotional coping with prognosis and adaptive response were associated with better QOL and less psychological distress, underscoring the need to develop interventions to promote coping with this treatment. Plain language summary: Patients undergoing chimeric antigen receptor T‐cell therapy experience report overly optimistic perceptions of their prognosis and have high rates of psychological distress.Notably, higher emotional coping with prognosis and adaptive response were associated with better quality of life and less psychological distress. Patients undergoing chimeric antigen receptor T‐cell therapy experience high psychological distress and report overly optimistic perception of their prognosis. Notably, high emotional coping with prognosis and adaptive response were associated with better quality of life and less psychological distress. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance

Author

Gaballa, Mahmoud R., primary, Ma, Junsheng, additional, Tanner, Mark R., additional, Al-Juhaishi, Taha, additional, Bashir, Qaiser, additional, Srour, Samer A., additional, Saini, Neeraj Y., additional, Ramdial, Jeremy L., additional, Nieto, Yago, additional, Murphy, Regan, additional, Rezvani, Katayoun, additional, Tang, Guilin, additional, Lee, Hans C., additional, Patel, Krina K., additional, Kaufman, Gregory P., additional, Manasanch, Elisabet E., additional, Ullah, Muhammad R., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2021
Full Text
View/download PDF

19. Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compression: When Chemotherapy Alone Is Enough

Author

Jang, Albert, Kram, Kallie N., Berger, Scott N., Gaballa, Mahmoud R., Lu, Lee B., Dunaway, David R., and Miller-Chism, Courtney N.

Subjects
Article Subject
Abstract

Spinal cord compression (SCC) is a rare initial presentation and complication of acute lymphoblastic leukemia (ALL) with nearly all reported cases occurring in the pediatric population. We report a 38-year-old previously healthy man who presented with acute on chronic lower back pain, gait instability, urinary retention, and severe thrombocytopenia. Radiologic examination revealed two soft tissue masses of the thoracic spine associated with compression fractures causing spinal canal narrowing and cord compression. Bone marrow biopsy confirmed the diagnosis of ALL. Immediate initiation of high-dose corticosteroids and systemic chemotherapy resolved the patient’s symptoms without radiation therapy or surgical intervention. After two courses of chemotherapy, the patient achieved complete remission in the bone marrow. Rapid administration of chemotherapy alone in this case resulted in a complete resolution of SCC. Given the rarity of this complication in adults, no standardized treatment has been established. The success of this case recommends chemotherapy as the initial management of SCC in chemotherapy-naïve ALL.

Published
2020
Full Text
View/download PDF

20. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.

Author

Gaballa, Mahmoud R., Ma, Junsheng, Tanner, Mark R., Al-Juhaishi, Taha, Bashir, Qaiser, Srour, Samer A., Saini, Neeraj Y., Ramdial, Jeremy L., Nieto, Yago, Murphy, Regan, Rezvani, Katayoun, Tang, Guilin, Lee, Hans C., Patel, Krina K., Kaufman, Gregory P., Manasanch, Elisabet E., Ullah, Muhammad R., Kebriaei, Partow, Thomas, Sheeba K., and Weber, Donna M.

Subjects
*MULTIPLE myeloma, *LENALIDOMIDE, *HEMATOPOIETIC stem cell transplantation
Abstract

Standard-of-care for newly-diagnosed, autologous hematopoietic stem cell transplantation (auto-HCT)-eligible, multiple myeloma (MM) patients includes bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by melphalan 200 mg/m2 (Mel200)-conditioned auto-HCT and lenalidomide maintenance. We completed a retrospective case series assessing outcomes of 187 MM patients who received this regimen at our institution. The 100-day non-relapse mortality incidence was zero. Before auto-HCT, 9.6 and 52.9% of patients achieved a complete response (CR) or ≥ very good partial response (VGPR), respectively. At day-100 post-transplant, 29.4 and 74.9% had achieved a CR/stringent-CR (sCR) or ≥ VGPR, respectively. At the last evaluation, 57.2% of patients had CR/sCR and 87.1% had ≥ VGPR. Median follow-up, progression-free survival (PFS), and overall survival (OS) were 63.2, 50, and 101.7 months, respectively. The 5-year PFS and OS were 43.1 and 79%. High-risk cytogenetics was associated with worse outcomes. This study illustrates that VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance are associated with good outcomes in MM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

Author

Gaballa, Mahmoud R., primary, Al-Juhaishi, Taha, additional, Bashir, Qaiser, additional, Srour, Samer A., additional, Saini, Neeraj, additional, Ramdial, Jeremy, additional, Nieto, Yago, additional, Murphy, Regan, additional, Lee, Hans C., additional, Patel, Krina K., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2020
Full Text
View/download PDF

24. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis

Author

Ramdial, Jeremy L., primary, Gaballa, Mahmoud R., additional, Al-Juhaishi, Taha, additional, Bashir, Qaiser, additional, Srour, Samer A., additional, Saini, Neeraj, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Popat, Uday R., additional, Murphy, Regan, additional, Lee, Hans C., additional, Patel, Krina K., additional, Manasanch, Elisabet E., additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Kaufman, Gregory P., additional, Orlowski, Robert Z., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2020
Full Text
View/download PDF

25. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.

Author

Oran, Amanda R., Adams, Clare M., Zhang, Xiao-Yong, Gennaro, Victoria J., Pfeiffer, Harla K., Mellert, Hestia S., Seidel, Hans E., Mascioli, Kirsten, Kaplan, Jordan, Gaballa, Mahmoud R., Shen, Chen, Rigoutsos, Isidore, King, Michael P., Cotney, Justin L, Arnold, Jamie J., Sharma, Suresh D., Martinez-Outshoorn, Ubaldo E., Vakoc, Christopher R., Chodosh, Lewis A., Thompson, James E., Bradner, James E., Cameron, Craig E., Shadel, Gerald S., Eischen, Christine M., McMahon, Steven B., Oran, Amanda R., Adams, Clare M., Zhang, Xiao-Yong, Gennaro, Victoria J., Pfeiffer, Harla K., Mellert, Hestia S., Seidel, Hans E., Mascioli, Kirsten, Kaplan, Jordan, Gaballa, Mahmoud R., Shen, Chen, Rigoutsos, Isidore, King, Michael P., Cotney, Justin L, Arnold, Jamie J., Sharma, Suresh D., Martinez-Outshoorn, Ubaldo E., Vakoc, Christopher R., Chodosh, Lewis A., Thompson, James E., Bradner, James E., Cameron, Craig E., Shadel, Gerald S., Eischen, Christine M., and McMahon, Steven B.

Abstract

Despite ubiquitous activation in human cancer, essential downstream effector pathways of the MYC transcription factor have been difficult to define and target. Using a structure/function-based approach, we identified the mitochondrial RNA polymerase (POLRMT) locus as a critical downstream target of MYC. The multifunctional POLRMT enzyme controls mitochondrial gene expression, a process required both for mitochondrial function and mitochondrial biogenesis. We further demonstrate that inhibition of this newly defined MYC effector pathway causes robust and selective tumor cell apoptosis, via an acute, checkpoint-like mechanism linked to aberrant electron transport chain complex assembly and mitochondrial reactive oxygen species (ROS) production. Fortuitously, MYC-dependent tumor cell death can be induced by inhibiting the mitochondrial gene expression pathway using a variety of strategies, including treatment with FDA-approved antibiotics. In vivo studies using a mouse model of Burkitt's Lymphoma provide pre-clinical evidence that these antibiotics can successfully block progression of MYC-dependent tumors.

Published
2016

26. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer

Author

Oran, Amanda R., primary, Adams, Clare M., additional, Zhang, Xiao-yong, additional, Gennaro, Victoria J., additional, Pfeiffer, Harla K., additional, Mellert, Hestia S., additional, Seidel, Hans E., additional, Mascioli, Kirsten, additional, Kaplan, Jordan, additional, Gaballa, Mahmoud R., additional, Shen, Chen, additional, Rigoutsos, Isidore, additional, King, Michael P., additional, Cotney, Justin L., additional, Arnold, Jamie J., additional, Sharma, Suresh D., additional, Martinez-Outschoorn, Ubaldo E., additional, Vakoc, Christopher R., additional, Chodosh, Lewis A., additional, Thompson, James E., additional, Bradner, James E., additional, Cameron, Craig E., additional, Shadel, Gerald S., additional, Eischen, Christine M., additional, and McMahon, Steven B., additional

Published
2016
Full Text
View/download PDF

28. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia

Author

Gaballa, Mahmoud R., Banerjee, Pinaki, Milton, DenáiR., Jiang, Xianli, Ganesh, Christina, Khazal, Sajad, Nandivada, Vandana, Islam, Sanjida, Kaplan, Mecit, Daher, May, Basar, Rafet, Alousi, Amin, Mehta, Rohtesh, Alatrash, Gheath, Khouri, Issa, Oran, Betul, Marin, David, Popat, Uday, Olson, Amanda, Tewari, Priti, Jain, Nitin, Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop, Chen, Ken, Champlin, Richard, Shpall, Elizabeth, Rezvani, Katayoun, and Kebriaei, Partow

Abstract

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single center phase II study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least one cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44-105). Twelvepatients (57%) completedall 4 treatment cycles.Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal.The cumulative incidence of acute GVHD grades 2-4 and 3-4 were 33% and 5%, respectively; two cases of mild (10%) and one case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival,progression-free survival, and non-relapse mortalityrates were 85%, 71%, and 0%, respectively. In a matched-analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab’s efficacy. Correlative studies of baseline and post-treatment samples identified patients with specific T-cell profiles as “responders” or “non-responders” to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets.Non-responders were T-cell deficient and expressed more inhibitory checkpoint molecules, including TIM3. We found that blinatumomab post-allogeneic HCT is feasible, andits benefit is dependent on the immune milieu at time of treatment.This paper is posted on ClinicalTrials.gov, study ID: NCT02807883.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results